Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: A case report and review of literature

Clinical Nephrology

Volumn 69, Issue 4, 2008, Pages 298-301

  Ahmed, M S ^a   Wong, C F ^a   Shawki, H ^b   Kapoor, N ^a   Pandya, B K ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antiviral therapy; Glomerulonephritis; Hepatitis C; MPGN

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PEGINTERFERON ALPHA; PREDNISOLONE; RIBAVIRIN; STEROID;

ADULT; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; CASE REPORT; COMPLEMENT BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG TOLERABILITY; FOLLOW UP; HEMATURIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS TYPE 1; NEPHROTIC SYNDROME; PROTEINURIA; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT; URINALYSIS;

EID: 42049103002     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69298     Document Type: Article

References (17)

1. Agnello V, Chung, RT, Kaplan, LM. A role for hepatitis C virus infection in Type II cryoglobulinemia. N Engl J Med. 1992; 327: 1490.
2. Ahmed MS, Wong CF. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J Nephrol. 2007; 20: 350-356.
3. Altraif IH, Abdulla AS, Al Sebayel MI et al. Hepatitis C-associated glomerulonephritis. Am J Nephrol. 1995; 15: 407-410.
4. Daghestani, L, Pomeroy, C. Renal manifestations of hepatitis C infection. Am J Med. 1999; 106: 347.
5. Johnson RJ, Gretch DR, Yamabe H et al. Mernbranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993; 328: 465.
6. Johnson RJ, Willson R, Yamabe H et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994a; 46: 1255.
7. Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virus-associated glomerulonephritis. Effect of (α-interferon therapy. Kidney Int. 1994b; 46: 1700.
8. Kamar N, Rostaing L, Alric L et al. Treatment of hepatitis C virus-related glomerulonephritis. Kidney Int. 2006; 69: 436-439.
9. Kitching AR, Holdsworth SR, Tipping PG et al. IFN-γ mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J Am Soc Nephrol. 1999; 10: 752-759.
10. Komatsuda A, Imai H, Wakui H et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med. 1996; 35: 529-533.
11. Lan HY, Bacher M, Yang N et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med. 1997; 185: 1455-1465
12. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345: 41-52.
13. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485-1492.
14. Ohta, S, Yokoyama H, Wada T et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis. 1999; 33: 1040.
15. Paleker NA. Extrahepatic manifestations of hepatitis C. South Med J. 2005; 98: 1019-1023.
16. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426-1432.
17. Sabry AA, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant. 2002; 17: 239.